Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

被引：0
|
作者：
Luisa Klotz
Berit Grützke
Maria Eveslage
Michael Deppe
Catharina C. Gross
Lucienne Kirstein
Anita Posevitz-Fejfar
Tilman Schneider-Hohendorf
Nicholas Schwab
Sven G. Meuth
Heinz Wiendl
机构：
[1] University Hospital Münster,Department of neurology
[2] Westfaelische Wilhelms-University Münster,Institute of biostatistics and clinical research
来源：
BMC Neurology | / 15卷
关键词：
Multiple sclerosis; Natalizumab; Fingolimod; PML; Switching;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
    Klotz, Luisa
    Gruetzke, Berit
    Eveslage, Maria
    Deppe, Michael
    Gross, Catharina C.
    Kirstein, Lucienne
    Posevitz-Fejfar, Anita
    Schneider-Hohendorf, Tilman
    Schwab, Nicholas
    Meuth, Sven G.
    Wiendl, Heinz
    BMC NEUROLOGY, 2015, 15
  • [2] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [3] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [4] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [5] Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
    Kalincik, Tomas
    Horakova, Dana
    Spelman, Tim
    Jokubaitis, Vilija
    Trojano, Maria
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Rozsa, Csilla
    Grammond, Pierre
    Alroughani, Raed
    Duquette, Pierre
    Girard, Marc
    Pucci, Eugenio
    Lechner-Scott, Jeannette
    Slee, Mark
    Fernandez-Bolanos, Ricardo
    Grand'Maison, Francois
    Hupperts, Raymond
    Verheul, Freek
    Hodgkinson, Suzanne
    Oreja-Guevara, Celia
    Spitaleri, Daniele
    Barnett, Michael
    Terzi, Murat
    Bergamaschi, Roberto
    McCombe, Pamela
    Sanchez-Menoyo, Jose
    Simo, Magdolna
    Csepany, Tunde
    Rum, Gabor
    Boz, Cavit
    Havrdova, Eva
    Butzkueven, Helmut
    ANNALS OF NEUROLOGY, 2015, 77 (03) : 425 - 435
  • [6] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [7] Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis
    Fakih, Ali Ussama
    Sahraian, Mohammad Ali
    Paybast, Sepideh
    Moghadasi, Abdorreza Naser
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [8] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [9] Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings
    Rinaldi, F.
    Seppi, D.
    Calabrese, M.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1640 - 1643
  • [10] Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Kalincik, T.
    Horakova, D.
    Spelman, T.
    Jokubaitis, V.
    Trojano, M.
    Lugaresi, A.
    Izquierdo, G.
    Rozsa, C.
    Grammond, P.
    Alroughani, R.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Lechner-Scott, J.
    Slee, M.
    Fernandez-Bolanos, R.
    Grand'Maison, F.
    Hupperts, R.
    Verheul, F.
    Hodgkinson, S.
    Oreja-Guevara, C.
    Spitaleri, D.
    Barnett, M.
    Terzi, M.
    Bergamaschi, R.
    McCombe, P.
    Sanchez-Menoyo, J.
    Simo, M.
    Csepany, T.
    Rum, G.
    Boz, C.
    Havrdova, E.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 195 - 196
12345